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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER2349Outcomes for Patients With HF and Preserved Ejection FractionRoss T. Campbell, Pardeep S. Jhund, Davide Castagno, Nathaniel M. Hawkins, Mark C. Petrie,
John J. V. McMurray
The Digitalis Investigation Group, the CHARM trials, and the I-Preserve Trials of patients
with heart failure and reduced or preserved ejection fraction (HFREF or HFPEF) provides
an opportunity to compare outcomes in these 2 types of heart failure (HF) and suggests
higher mortality for HFREF. Further comparison of the patients in these trials in patients
with similar cardiac risk factors but no HF enrolled in other trials shows that HFPEF is
associated with higher rates of cardiovascular death and HF hospitalization. Campbell and
colleagues conclude that the poor clinical outcomes in patients with (HFPEF) are not easily
explained on the basis of age, gender, comorbidity, blood pressure, or left ventricular structural
remodeling.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY
2357Increased Risk of Death or MI Shortly After Discontinuation of
Long-Term Clopidogrel Therapy in Patients With Previous SVG PCIAmit Sachdeva, Sumati Bavisetty, Gerald Beckham, Albert Y.-J. Shen, Vicken Aharonian,
Prakash Mansukhani, Gregg W. Stone, Martin Leon, Jeffrey Moses, Naing Moore, Ric Hyett,
Richard Contreras, Somjot S. Brar
Sachdeva and colleagues performed a retrospective cohort study to determine the risk of death
and myocardial infarction (MI) following clopidogrel discontinuation in patients after
percutaneous coronary intervention (PCI) in a saphenous vein graft (SVG). The incidence
rate per 1,000 person-days of death or MI after stopping clopidogrel was 1.26 for days 0 to
90, 0.41 for days 91 to 365, and 0.41 for years 1 to 2. The results were consistent across
subgroups including stent type and diabetes status, and after controlling for patients who
stopped clopidogrel due to bleeding complications.(continued on page A-24)
DECEMBER 11, 2012 (continued) A-24CARDIOMETABOLIC RISK2364Early Lipid Levels More Predictive of CAC Than Recent Levels or GRSConnie W. Tsao, Sarah Rosner Preis, Gina M. Peloso, Shih-Jen Hwang, Sekar Kathiresan, Caroline S. Fox,
L. Adrienne Cupples, Udo Hoffmann, Christopher J. O’Donnell
Tsao and colleagues used data from the Framingham Heart Studies (FHS) to compare the
accuracy of long-term versus contemporary lipid levels for predicting coronary artery calcium
(CAC). The results were also compared to several lipid genetic risk scores (GRS). FHS
participants underwent serial fasting lipids tests between 1970 to 2000 and computed
tomography measured CAC (2002 to 2005). Previously described lipid GRSs were computed
from single nucleotide polymorphisms. The first measurement and the long-term average
lipid measurements were more strongly associated with CAC than contemporary
measurements. The low-density lipoprotein cholesterol GRS was associated with CAC, but
did not provide additive information to the lipid measurements.CARDIOMETABOLIC RISK2372Dysfunctional HDL in Chronic Hemodialysis PatientsSuguru Yamamoto, Patricia G. Yancey, T. Alp Ikizler, W. Gray Jerome, Ryohei Kaseda, Brian Cox,
Aihua Bian, Ayumi Shintani, Agnes B. Fogo, MacRae F. Linton, Sergio Fazio, Valentina Kon
Yamamoto and colleagues examined the antiatherogenic effects of high-density lipoprotein
(HDL) in individuals with end-stage renal disease on dialysis (ESRD-HD). Cellular
cholesterol efflux and inflammatory response were assessed in macrophages exposed to HDL
of ESRD-HD patients or healthy controls. HDL from ESRD-HD was dramatically less
effective than control HDL in accepting cholesterol from macrophages; it also increased
macrophage cytokine response. These findings suggest that chronic dialysis patients have
dysfunctional HDL.
Editorial Comment: Chunyu Zheng, Masanori Aikawa, page 2380(continued on page A-25)
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2384Statins Reduce the Risk of HF in Breast
Cancer Patients Receiving Anthracycline ChemotherapySinziana Seicean, Andreea Seicean, Juan Carlos Plana, G. Thomas Budd, Thomas H. Marwick
Seicean and colleagues performed a retrospective case-control study to evaluate the effect of
statin treatment on new-onset heart failure (HF) in breast cancer patients receiving
anthracycline-based chemotherapy. A total of 67 patients receiving uninterrupted statin
therapy were compared to 134 propensity-matched controls. There was a significantly lower
hazard ratio (0.3) for heart failure in patients taking uninterrupted statin therapy. The lower
rates of HF among statin-treated subjects is consistent with prior animal studies, and warrants
further investigation through prospective randomized clinical trials.Editorial Comment: Daniel J. Lenihan, page 2391HEART RHYTHM DISORDERS
2393A Novel Low-Energy Electrotherapy That
Terminates VT With Lower Energy Than a Biphasic ShockAjit H. Janardhan, Wenwen Li, Vadim V. Fedorov, Michael Yeung, Michael J. Wallendorf,
Richard B. Schuessler, Igor R. Efimov
Janardhan and colleagues sought to develop a low-energy electrotherapy that terminates
ventricular tachycardia (VT) when anti-tachycardia pacing (ATP) fails. Multistage
electrotherapy (MSE) consisting of 3 monophasic (MP) shocks delivered within 1 VT cycle
length (CL), followed by 6 MP shocks, followed by ATP was compared to other algorithms
in a dog model. The mean defibrillation threshold (DFT) of MSE was significantly lower
than that of a single biphasic shock in terms of total energy and peak shock voltage. At a peak
shock amplitude of 20 V, MSE achieved a 91% rate of terminations compared to only 11% for a
biphasic shock. While more testing in humans is needed, this strategy may safely terminate VT
with less myocardial and psychological damage than traditional biphasic defibrillation.
Editorial Comment: Roger A. Winkle, page 2399(continued on page A-26)
DECEMBER 11, 2012 (continued) A-26CARDIAC IMAGING2402Diffuse Ventricular Fibrosis Detected by CMR in Patients With AFLiang-han Ling, Peter M. Kistler, Andris H. Ellims, Leah M. Iles, Geraldine Lee, Gerard L. Hughes,
Jonathan M. Kalman, David M. Kaye, Andrew J. Taylor
Diffuse myocardial fibrosis, unlike replacement fibrosis, is not visualized on delayed-
enhancement cardiac magnetic resonance imaging (CMR), but may be quantified with
contrast-enhanced T1 mapping methods. Nazarian and colleagues reviewed CMR data to
determine if diffuse myocardial fibrosis is associated with atrial fibrillation (AF). The results
showed that post-contrast ventricular T1 time was longest in patients with no history of AF,
shorter in those with paroxysmal AF and shortest in those with persistent AF. These results
suggest diffuse LV fibrosis frequently accompanies AF.Editorial Comment: Henry R. Halperin, Saman Nazarian, page 2409CONGENITAL HEART DISEASE
2411Survey of U.S. Pediatric Cardiologists
Reveals Low Rates of Referrals to ACHD ProvidersSusan M. Fernandes, Paul Khairy, Laurie Fishman, Patrice Melvin, Joanne O’Sullivan-Oliveira,
Gregory S. Sawicki, Sonja Ziniel, Petar Breitinger, Roberta Williams, Masato Takahashi, Michael J. Landzberg
Guidelines recommend adults with moderate/complex congenital heart disease (CHD) be
treated by clinicians trained in adult congenital heart disease (ACHD). Fernandes and
colleagues surveyed pediatric cardiologists (PCs) to elucidate referral patterns and perceived
barriers to ACHD care. The most commonly perceived patient characteristic prompting
referral to ACHD care was adult comorbidities. The most frequently perceived barrier to
ACHD care was emotional attachment of parents and patients to the PC. A lack of qualified
ACHD care providers was also frequently identified. These findings may assist ACHD
programs in developing strategies to improve collaborative care and address emotional needs
during the transition and transfer process.
